---
title: "ADC Therapeutics SA (ADCT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ADCT.US.md"
symbol: "ADCT.US"
name: "ADC Therapeutics SA"
industry: "Biotechnology"
datetime: "2026-06-13T14:34:00.606Z"
locales:
  - [en](https://longbridge.com/en/quote/ADCT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ADCT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ADCT.US.md)
---

# ADC Therapeutics SA (ADCT.US)

## Company Overview

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs).

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.adctherapeutics.com](https://www.adctherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-13T04:30:12.000Z

**Overall: D (0.60)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 270 / 390 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 4.43% |  |
| Net Profit YoY | 8.58% |  |
| P/B Ratio | -0.62 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 133550715.90 |  |
| Revenue | 79175000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 60.27% | A |
| Profit Margin | -173.02% | E |
| Gross Margin | -12.67% | E |
| Revenue YoY | 4.43% | C |
| Net Profit YoY | 8.58% | C |
| Total Assets YoY | 6.96% | B |
| Net Assets YoY | 9.17% | B |
| Cash Flow Margin | 83.62% | C |
| OCF YoY | 4.43% | C |
| Turnover | 0.28 | D |
| Gearing Ratio | 174.23% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - ADC Therapeutics SA",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "4.43%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "8.58%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-0.62",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "133550715.90",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "79175000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "60.27%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-173.02%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-12.67%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "4.43%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "8.58%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "6.96%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "9.17%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "83.62%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "4.43%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.28",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "174.23%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.97 | 183/390 | - | - | - |
| PB | -0.62 | 478/390 | - | - | - |
| PS (TTM) | 1.69 | 46/390 | 6.54 | 5.86 | 4.65 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | CapForce Inc. (CFOR.US) | A | A | A | A | B | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-06-10T04:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 60% |
| Hold | 2 | 40% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.05 |
| Highest Target | 10.00 |
| Lowest Target | 6.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ADCT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ADCT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ADCT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ADCT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**